• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical ophthalmology >Only first intravitreal bevacizumab injection achieves statistically significant visual improvement in na?ve myopic choroidal neovascularization
【24h】

Only first intravitreal bevacizumab injection achieves statistically significant visual improvement in na?ve myopic choroidal neovascularization

机译：仅初次玻璃体内贝伐单抗注射可使初次近视脉络膜新生血管获得明显的视觉改善

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: The aim of this study was to evaluate the efficacy of intravitreal bevacizumab when administered on an as-needed basis for the treatment of myopic choroidal neovascularization (CNV), and to assess visual changes upon treatment.Methods: This study was designed as a retrospective, interventional case series, for which the inclusion criteria were pathologic myopia, and documentation of untreated active macular CNV on fluorescein angiography and optical coherence tomography. Monthly changes in best-corrected visual acuity (BCVA), visual gain after each treatment, and correlation with refraction, age, location, and dimension of CNV were considered. The data were analyzed using the one-tailed, paired Wilcoxon test.Results: Nineteen naive eyes were found suitable for the study. The mean number of treatments was 3.32 ± 2.36 (confidence interval 2.25–4.37) during a mean follow-up period of 18.95 ± 8.3 months. At baseline, mean BCVA was 0.58 ± 0.37 logarithm of the minimum angle of resolution (logMAR) units. At 12 months, mean BCVA was 0.39 ± 0.35 logMAR and at 24 months was 0.39 ± 0.40. Mean improvement in BCVA from baseline was +0.17 ± 0.25 logMAR (P < 0.05) at month 12, +0.14 ± 0.25 logMAR (P = 0.1) at month 18, and +0.09 ± 0.32 logMAR (P = 0.5) at month 24. Improvement on pretreatment BCVA was significant (+0.16 logMAR, P < 0.01) after the first injection, but not after the second (?0.01 logMAR, P = 0.5) or third (+0.02 logMAR, P = 0.5) injections. There was a statistically significant correlation between age and number of treatments, and between improvement in BCVA of foveal versus extrafoveal location of CNV.Conclusion: The use of intravitreal bevacizumab "as needed" is an effective treatment for myopic CNV, but visual gain is statistically significant only after the first injection and decreases in the second year.
机译：背景：本研究的目的是评估按需给药时玻璃体内贝伐单抗治疗近视脉络膜新生血管（CNV）的疗效，并评估治疗后的视觉变化。回顾性，介入病例系列，纳入标准为病理性近视，并在荧光素血管造影和光学相干断层扫描上记录未经治疗的活动性黄斑CNV。考虑最佳矫正视力（BCVA），每次治疗后视力获得的每月变化，以及与CNV的屈光度，年龄，位置和尺寸的相关性。使用单尾成对的Wilcoxon检验对数据进行分析。结果：发现有十九只幼稚的眼睛适合该研究。平均随访期为18.95±8.3个月，平均治疗次数为3.32±2.36（置信区间2.25–4.37）。在基线时，平均BCVA为最小分辨角（logMAR）单位的0.58±0.37对数。 12个月时的平均BCVA为0.39±0.35 logMAR，24个月时的平均BCVA为0.39±0.40。 BCVA在第12个月时相对于基线的平均改善为+0.17±0.25 logMAR（P <0.05），在第18个月时为+0.14±0.25 logMAR（P = 0.1），以及在第24个月时为+0.09±0.32 logMAR（P = 0.5）。第一次注射后，BCVA预处理的改善显着（+0.16 logMAR，P <0.01），但第二次（≥0.01logMAR，P = 0.5）或第三次（+0.02 logMAR，P = 0.5）注射后没有改善。在年龄和治疗次数之间，在中央凹的中央凹与中央凹的BCVA改善之间存在统计学上的显着相关。结论：“根据需要”使用玻璃体内贝伐单抗对近视CNV是一种有效的治疗方法，但在视觉上有统计学意义仅在第一次注射后显着，第二年减少。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号